Description

Lobradimil (RMP 7), a synthetic bradykinin analog, is a potent and selective bradykinin B2 receptor agonist (Ki: 0.54 nM). Lobradimil increases the permeability of the BBB. Lobradimil can be used in the research of brain tumors[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–Cancer-programmed cell death–C49H75N15O12S—-[1]Warren K, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group. Cancer Chemother Pharmacol. 2006 Sep;58(3):343-7. |[2]Elliott PJ, et al. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology. 1996 Jun;33(1-3):205-8. |[3]Doctrow SR, et al. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther. 1994 Oct;271(1):229-37. |[4]Mackic JB, et al. Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharm Res. 1999 Sep;16(9):1360-5.–159768-75-9–1098.28–99.51–O=C([C@H]1N(CCC1)C([C@@H](N)CCCNC(N)=N)=O)N2[C@@H](C[C@H](C2)O)C(NCC(N[C@H](C(N[C@@H](CO)C(N3[C@@H](CCC3)C(N[C@H](CN[C@H](C(O)=O)CCCNC(N)=N)CC4=CC=C(C=C4)OC)=O)=O)=O)CC5=CC=CS5)=O)=O–Cancer–H2O : ≥ 50 mg/mL–Bradykinin Receptor–Bradykinin B2 Receptor (B2R)–GPCR/G Protein–Peptides